Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2005-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1124/JPET.104.073692PMID 15340016
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of arsenic-induced prolongation of cardiac repolarization.

  2004influential reference
• Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action

  2004cited by this paper
• Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

  2003cited by this paper
• Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.

  2003cited by this paper
• Catalytic topoisomerase II inhibitors in cancer therapy.

  2003cited by this paper
• Role of the Cytosolic Chaperones Hsp70 and Hsp90 in Maturation of the Cardiac Potassium Channel hERG

  2003influential reference
• The impact of drug-induced QT interval prolongation on drug discovery and development

  2003cited by this paper
• T Wave Alternans and Torsades de Pointes After the Use of Intravenous Pentamidine

  2002cited by this paper
• Pentamidine is an inhibitor of PRL phosphatases with anticancer activity.

  2002cited by this paper
• Chemotherapy of human African trypanosomiasis.

  2002cited by this paper
• Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics.

  2001cited by this paper
• Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana.

  2001cited by this paper
• Molecular and cellular mechanisms of cardiac arrhythmias.

  2001cited by this paper
• Molecular basis of functional voltage‐gated K+ channel diversity in the mammalian myocardium

  2000cited by this paper
• A trafficking checkpoint controls GABA(B) receptor heterodimerization.

  2000cited by this paper
• Synthetic DNA minor groove-binding drugs.

  1999cited by this paper
• Direct measurement of cell numbers in microtitre plate cultures using the fluorescent dye SYBR green I.

  1998cited by this paper
• Dynamic analysis of dofetilide‐induced changes in ventricular repolarization

  1998cited by this paper
• In-vitro activity of topoisomerase inhibitors against Pneumocystis carinii.

  1997cited by this paper
• Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia.

  1997cited by this paper
• A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients.

  1997cited by this paper
• Plasma pentamidine concentrations vary between individuals with Pneumocystis carinii pneumonia and the drug is actively secreted by the kidney.

  1994cited by this paper
• Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients.

  1994cited by this paper
• Incidence of QT interval prolongation during pentamidine therapy of Pneumocystis carinii pneumonia.

  1991cited by this paper
• Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity.

  1988cited by this paper
• Pentamidine isethionate. A review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia.

  1987influential reference
• Torsade de pointes during administration of pentamidine isethionate.

  1987influential reference
• Use of a specific and sensitive assay to determine pentamidine pharmacokinetics in patients with AIDS.

  1986cited by this paper
• Pentamidine: a review.

  1985cited by this paper
• Electrophysiological effects of labetolol on rabbit atrial, ventricular and Purkinje cells, in normoxia and hypoxia.

  1982cited by this paper

• Arrhythmia Risk Predictions from Molecular Simulations of Cardiac Ion Channel-Drug Interactions.

  2025cites this paper
• Prediction of TdP Arrhythmia Risk Through Molecular Simulations of Conformation-specific Drug Interactions with the hERG K+, Nav1.5, and Cav1.2 Channels

  2025cites this paper
• Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients

  2025cites this paper
• Mitigation of Injury from Myocardial Infarction by Pentamidine, an Inhibitor of the Acetyltransferase Tip60

  2025cites this paper
• Whole‐Cell Configuration of the Patch‐Clamp Technique in the hERG Channel Assay

  2024cites this paper
• The posterity of Zebrafish in paradigm of in vivo molecular toxicological profiling.

  2024cites this paper
• Discovery of Potent STT3A/B Inhibitors and Assessment of Their Multipathogen Antiviral Potential and Safety.

  2024cites this paper
• Torsades de pointe : implications de l’axe neuro-cardiaque

  2024cites this paper
• Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study

  2023cites this paper
• Structural analysis of hERG channel blockers and the implications for drug design.

  2023cites this paper
• Long-term in vitro recording of cardiac action potentials on microelectrode arrays for chronic cardiotoxicity assessment

  2023cites this paper
• Designing peptide amphiphiles as novel antibacterials and antibiotic adjuvants against gram-negative bacteria.

  2023cites this paper
• Evaluation of chronic drug-induced electrophysiological and cytotoxic effects using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)

  2023cites this paper
• Synergy by Perturbing the Gram-Negative Outer Membrane: Opening the Door for Gram-Positive Specific Antibiotics

  2022cites this paper
• New Insights into Ion Channels: Predicting hERG-Drug Interactions

  2022cites this paper
• The Challenges of Predicting Drug-Induced QTc Prolongation in Humans

  2022cites this paper
• Selective delivery of pentamidine toward cancer cells by self-assembled nanoparticles.

  2022cites this paper
• Nanotechnological approaches for pentamidine delivery

  2022cites this paper
• Thyroid hormones regulate cardiac repolarization and QT-interval related gene expression in hiPSC cardiomyocytes

  2022cites this paper
• Chronic cardiotoxicity assessment by cell optoporation on microelectrode arrays

  2022cites this paper
• Preclinical Development of Pentamidine Analogs Identifies a Potent and Nontoxic Antibiotic Adjuvant.

  2022cites this paper
• Functional human cell-based vascularised cardiac tissue model for biomedical research and testing

  2022cites this paper
• Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in hERG Assays

  2022cites this paper
• Genetic and Molecular Aspects of Drug-Induced QT Interval Prolongation

  2021cites this paper
• Ventricular voltage‐gated ion channels: Detection, characteristics, mechanisms, and drug safety evaluation

  2021cites this paper
• COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels

  2021cites this paper
• Cardiac hERG K+ Channel as Safety and Pharmacological Target.

  2021cites this paper
• Parent and Metabolite Concentration-QT Modeling to Evaluate QT-Interval Prolongation at Savolitinib Therapeutic Doses

  2021cites this paper
• Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel

  2020cites this paper
• CHO-hERG DUO tested on QPatch in multi-hole mode

  2020cites this paper
• CHLOROQUINE AND AZITHROMYCIN INDUCED QTC PROLONGATION IN COVID-19 PATIENTS

  2020cites this paper
• LUF7244 plus Dofetilide Rescues Aberrant Kv11.1 Trafficking and Produces Functional IKv11.1

  2020cites this paper
• Drug-likeness of linear pentamidine analogues and their impact on the hERG K+ channel – correlation with structural features

  2019cites this paper
• Electrophysiological evaluation of pentamidine and 17‐AAG in human stem cell‐derived cardiomyocytes for safety assessment

  2019cites this paper
• Mitragynine, an euphoric compound inhibits hERG1a/1b channel current and upregulates the complexation of hERG1a-Hsp90 in HEK293-hERG1a/1b cells

  2019cites this paper
• Long-term functional and structural preservation of precision-cut human myocardium under continuous electromechanical stimulation in vitro

  2019cites this paper
• Modeling cardiac complexity: Advancements in myocardial models and analytical techniques for physiological investigation and therapeutic development in vitro

  2019cites this paper
• Impact of calcium-sensitive dyes on the beating properties and pharmacological responses of human iPS-derived cardiomyocytes using the calcium transient assay.

  2018cites this paper
• Cardiovascular safety of prokinetic agents: A focus on drug‐induced arrhythmias

  2018cites this paper
• Targeting Trafficking in Drug Development

  2018cites this paper
• Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator and Drugs: Insights from Cellular Trafficking.

  2018cites this paper
• Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.

  2017cites this paper
• The effects of deoxyelephantopin on the cardiac delayed rectifier potassium channel current (IKr) and human ether-a-go-go-related gene (hERG) expression.

  2017cites this paper
• Molecular Pathophysiology of Congenital Long QT Syndrome.

  2017cites this paper
• Proarrhythmic risk assessment using conventional and new in vitro assays

  2017cites this paper
• Clenbuterol Attenuates hERG Channel by Promoting the Mature Channel Degradation

  2017cites this paper
• Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism

  2017cites this paper
• Antimicrobials and QT prolongation.

  2017cites this paper
• Cardiotoxic effect of levofloxacin and ciprofloxacin in rats with/without acute myocardial infarction: Impact on cardiac rhythm and cardiac expression of Kv4.3, Kv1.2 and Nav1.5 channels.

  2017cites this paper
• Synthesis and Characterization of Graphene like Carbon Nanosheet: Interaction with some Drug Molecules and Anticancer Activity

  2017cites this paper
• Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias

  2017cites this paper
• Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro‐arrhythmia Assay initiative studies

  2017cites this paper
• β-Arrestin-Mediated Regulation of the Human Ether-a-go-go-Related Gene Potassium Channel

  2017cites this paper
• Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti‐Infective Agents: A Systematic Literature Review From the ARITMO Project

  2017cites this paper
• hERG quality control and the long QT syndrome

  2016cites this paper
• Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias

  2016cites this paper
• Safety pharmacology studies using EFP and impedance.

  2016cites this paper
• Impaired Inactivation of L-Type Ca2+ Current as a Potential Mechanism for Variable Arrhythmogenic Liability of HERG K+ Channel Blocking Drugs

  2016cites this paper
• Evolution of strategies to improve preclinical cardiac safety testing

  2016cites this paper
• Predicting drug‐induced QT prolongation and torsades de pointes

  2016cites this paper
• Mitragynine and its potential blocking effects on specific cardiac potassium channels.

  2016cites this paper
• Propofol inhibits hERG K+ channels and enhances the inhibition effects on its mutations in HEK293 cells.

  2016cites this paper
• Lysosomes and Phospholipidosis in Drug Development and Regulation

  2016cites this paper
• Cardiac Delayed Rectifier Potassium Channels in Health and Disease.

  2016cites this paper
• Human Pluripotent Stem Cell‐Derived Cardiomyocytes

  2016cites this paper
• Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging.

  2016cites this paper
• Improved Prediction of Drug‐Induced Torsades de Pointes Through Simulations of Dynamics and Machine Learning Algorithms

  2016cites this paper
• A Simple Protocol for the Myocardial Differentiation of Human iPS Cells.

  2015cites this paper
• Control of Cardiac Repolarization by Phosphoinositide 3-Kinase Signaling to Ion Channels

  2015cites this paper
• CiPA: Ongoing testing, future qualification procedures, and pending issues.

  2015cites this paper
• Cellular and Molecular Perspectives on Cardiac Toxins

  2015cites this paper
• Clinical ECG Assessment.

  2015cites this paper
• A Human Induced Pluripotent Stem Cell−Derived Cardiomyocyte (hiPSC‐CM) Multielectrode Array Assay for Preclinical Cardiac Electrophysiology Safety Screening

  2015cites this paper
• Rab11-dependent Recycling of the Human Ether-a-go-go-related Gene (hERG) Channel*

  2015influential citation
• Assessment of the effect of ofatumumab on cardiac repolarization

  2015cites this paper
• Regulation of the Human Ether‐a‐go‐go Related Gene (hERG) Potassium Channel by Nedd4 Family Interacting Proteins (Ndfips)

  2015cites this paper
• The protease inhibitor atazanavir blocks hERG K+ channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane

  2015cites this paper
• Pro-Arrhythmic Effects of Noncardiac Medications: Lessons From Macrolide Antibiotics.

  2015cites this paper
• Screening for Acute IKr Block Is Insufficient to Detect Torsades de Pointes Liability: Role of Late Sodium Current

  2014cites this paper
• Up-Regulation of hERG K+ Channels by B-RAF

  2014cites this paper
• Safety Pharmacology II-CV, GI, Respiratory and Renal Safety

  2014cites this paper
• Pharmacology of voltage-gated potassium channel Kv1.5--impact on cardiac excitability.

  2014cites this paper
• Effect of terfenadine and pentamidine on the HERG channel and its intracellular trafficking: combined analysis with automated voltage clamp and confocal microscopy.

  2014cites this paper
• 13th Annual Meeting of the Safety Pharmacology Society: focus on novel technologies and safety pharmacology frontiers

  2014cites this paper
• Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative

  2014cites this paper
• Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents.

  2014cites this paper
• Cardiac and renal inward rectifier potassium channel pharmacology: emerging tools for integrative physiology and therapeutics.

  2014cites this paper
• Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity

  2014cites this paper
• In vitro-in vivo extrapolation of drug-induced proarrhythmia predictions at the population level.

  2014cites this paper
• Use of Human Embryonic Stem Cell-Derived Cardiomyocyte Clusters to Assess Potential for Chronic Treatment with Compounds to Cause QT Prolongation

  2014cites this paper
• The rescuable function and mechanism of resveratrol on As2O3-induced hERG K+ channel deficiency

  2014cites this paper
• Drug Discovery vs hERG

  2014cites this paper
• Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.

  2013cites this paper
• A ropinirol és a rosiglitazon proarrhythmiás hatásának vizsgálata kutya kamrai szívizomsejteken

  2013cites this paper
• Endocytosis of hERG Is Clathrin-Independent and Involves Arf6

  2013cites this paper
• Acquired (Drug-Induced) Long and Short QT Syndromes

  2013cites this paper
• Blockage of hERG current and the disruption of trafficking as induced by roxithromycin.

  2013cites this paper
• Regulation of the Human Ether-a-go-go-related Gene (hERG) Channel by Rab4 Protein through Neural Precursor Cell-expressed Developmentally Down-regulated Protein 4-2 (Nedd4-2)*

  2013cites this paper
• Assessment of the cardiac safety and pharmacokinetics of a short course, twice daily dose of orally-administered mifepristone in healthy male subjects.

  2013cites this paper
• Efficient and specific cardiac IK₁ inhibition by a new pentamidine analogue.

  2013cites this paper